JP2005515992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515992A5 JP2005515992A5 JP2003548815A JP2003548815A JP2005515992A5 JP 2005515992 A5 JP2005515992 A5 JP 2005515992A5 JP 2003548815 A JP2003548815 A JP 2003548815A JP 2003548815 A JP2003548815 A JP 2003548815A JP 2005515992 A5 JP2005515992 A5 JP 2005515992A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- use according
- degeneration
- phenol
- retinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 230000003054 hormonal effect Effects 0.000 claims description 7
- -1 contact lens Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 5
- 208000017442 Retinal disease Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940011871 estrogen Drugs 0.000 claims 5
- 239000000262 estrogen Substances 0.000 claims 5
- 125000003367 polycyclic group Chemical group 0.000 claims 5
- 206010038923 Retinopathy Diseases 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- ZYUVGYBAPZYKSA-UHFFFAOYSA-N 5-(3-hydroxybutan-2-yl)-4-methylbenzene-1,3-diol Chemical group CC(O)C(C)C1=CC(O)=CC(O)=C1C ZYUVGYBAPZYKSA-UHFFFAOYSA-N 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 230000001384 anti-glaucoma Effects 0.000 claims 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- 208000020911 optic nerve disease Diseases 0.000 claims 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 2
- 150000003180 prostaglandins Chemical group 0.000 claims 2
- 229940127293 prostanoid Drugs 0.000 claims 2
- 150000003814 prostanoids Chemical class 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 1
- WTPCCFHCHCMJIT-UHFFFAOYSA-N 1,2,5-oxathiazine Chemical compound O1SC=CN=C1 WTPCCFHCHCMJIT-UHFFFAOYSA-N 0.000 claims 1
- PPYNEJLGBMVWMC-UHFFFAOYSA-N 1,2,6-oxathiazine Chemical compound O1SC=CC=N1 PPYNEJLGBMVWMC-UHFFFAOYSA-N 0.000 claims 1
- VCZQYTJRWNRPHF-UHFFFAOYSA-N 1,2-dioxin Chemical compound O1OC=CC=C1 VCZQYTJRWNRPHF-UHFFFAOYSA-N 0.000 claims 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 claims 1
- HPYLZSUEFFQHRS-UHFFFAOYSA-N 2h-1,2,4-oxadiazine Chemical compound N1OC=CN=C1 HPYLZSUEFFQHRS-UHFFFAOYSA-N 0.000 claims 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 1
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 claims 1
- UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 claims 1
- BYVSMDBDTBXASR-UHFFFAOYSA-N 5,6-dihydro-4h-oxazine Chemical compound C1CON=CC1 BYVSMDBDTBXASR-UHFFFAOYSA-N 0.000 claims 1
- 201000009487 Amblyopia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 claims 1
- 208000033810 Choroidal dystrophy Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 claims 1
- 208000037312 Familial drusen Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 206010058046 Post procedural complication Diseases 0.000 claims 1
- 208000035965 Postoperative Complications Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010038897 Retinal tear Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 claims 1
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 claims 1
- 208000014769 Usher Syndromes Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 230000004456 color vision Effects 0.000 claims 1
- 201000006754 cone-rod dystrophy Diseases 0.000 claims 1
- 208000006623 congenital stationary night blindness Diseases 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 238000013532 laser treatment Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 208000030194 mouth disease Diseases 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 238000005204 segregation Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 10
- 229960005309 estradiol Drugs 0.000 description 6
- VOXZDWNPVJITMN-QXDIGNSFSA-N (8s,9r,13r,14r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@@H]3CC[C@@](C)([C@@H](CC4)O)[C@H]4[C@H]3CCC2=C1 VOXZDWNPVJITMN-QXDIGNSFSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229920000379 polypropylene carbonate Polymers 0.000 description 2
- 238000002300 pressure perturbation calorimetry Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33659901P | 2001-12-05 | 2001-12-05 | |
| PCT/US2002/039098 WO2003047559A1 (en) | 2001-12-05 | 2002-12-05 | Use of polycyclic phenolic compounds for the treatment of opthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005515992A JP2005515992A (ja) | 2005-06-02 |
| JP2005515992A5 true JP2005515992A5 (https=) | 2006-01-26 |
Family
ID=23316822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548815A Pending JP2005515992A (ja) | 2001-12-05 | 2002-12-05 | 眼病治療のための多環式フェノール化合物の使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030105167A1 (https=) |
| EP (1) | EP1463494A1 (https=) |
| JP (1) | JP2005515992A (https=) |
| AU (1) | AU2002359635A1 (https=) |
| CA (1) | CA2468342A1 (https=) |
| WO (1) | WO2003047559A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070213310A1 (en) * | 2002-04-01 | 2007-09-13 | Laszlo Prokai | Prodrugs for Use as Ophthalmic Agents |
| US7300926B2 (en) * | 2002-04-01 | 2007-11-27 | University Of Florida Research Foundation, Inc. | Steroidal quinols and their use for estrogen replacement therapy |
| US7186707B2 (en) * | 2002-04-01 | 2007-03-06 | University Of Florida | Prodrugs for use as ophthalmic agents |
| ES2279946T3 (es) * | 2002-04-01 | 2007-09-01 | University Of Florida Research Foundation, Inc. | Quinoles esteroideos como profarmacos de antioxidantes. |
| US7578996B2 (en) * | 2004-04-07 | 2009-08-25 | Advanced Medical Optics, Inc. | Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions |
| US6973795B1 (en) * | 2004-05-27 | 2005-12-13 | American Standard International Inc. | HVAC desiccant wheel system and method |
| US20060188492A1 (en) * | 2005-01-13 | 2006-08-24 | Chronorx Llc, An Alaska Limited Liability Company | Topical management of ocular and periocular conditions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US6350739B1 (en) * | 1999-08-11 | 2002-02-26 | University Of Florida Resarch Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
| US6197833B1 (en) * | 1995-07-24 | 2001-03-06 | Apollo Biopharmaceutics, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
| US5877169A (en) * | 1993-11-05 | 1999-03-02 | University Of Florida Research Foundation, Inc. | Methods of treatment of ischemic damage |
| US6319914B1 (en) * | 1993-11-05 | 2001-11-20 | Apollo Biopharmaceuticals, Inc. | Cytoprotective effect of polycyclic phenolic compounds |
| US5859001A (en) * | 1996-01-11 | 1999-01-12 | University Of Florida Research Foundation, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
| DE19654750A1 (de) * | 1996-12-30 | 1998-07-02 | Helmut Dr Med Zander | Verwendung von Wirkstoffen mit Östrogen-Wirkung zur Vorbeugung und Behandlung von Makuladegeneration |
| EP0977578B1 (en) * | 1997-01-16 | 2004-03-31 | University Of Florida Research Foundation, Inc. | Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| EP1032397A1 (en) * | 1997-11-24 | 2000-09-06 | University Of Florida Research Foundation, Inc. | Testosterone inhibitors and use for the protection of neurons |
| CA2321560C (en) * | 1998-03-13 | 2007-05-22 | Johns Hopkins University School Of Medicine | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| US6326365B1 (en) * | 1999-07-20 | 2001-12-04 | Apollo Biopharmaceutics, Inc. | Methods of prevention and treatment of ischemic damage |
| US6339078B1 (en) * | 1999-07-20 | 2002-01-15 | University Of Florida Research Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| ES2287184T3 (es) * | 2000-11-03 | 2007-12-16 | Washington University | Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora. |
-
2002
- 2002-12-05 CA CA002468342A patent/CA2468342A1/en not_active Abandoned
- 2002-12-05 JP JP2003548815A patent/JP2005515992A/ja active Pending
- 2002-12-05 AU AU2002359635A patent/AU2002359635A1/en not_active Abandoned
- 2002-12-05 EP EP02794186A patent/EP1463494A1/en not_active Withdrawn
- 2002-12-05 WO PCT/US2002/039098 patent/WO2003047559A1/en not_active Ceased
- 2002-12-05 US US10/313,172 patent/US20030105167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McGhee et al. | Locally administered ocular corticosteroids: benefits and risks | |
| US20200323685A1 (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| CA2671769A1 (en) | Treatment for dry eye | |
| JP2011502990A (ja) | 薬物送達用ビヒクルとしての水非混和性物質 | |
| JPH04221322A (ja) | 眼病用製剤 | |
| JP2005515992A5 (https=) | ||
| KR20070040326A (ko) | 백내장, 황반 변성 및 다른 안과 질환의 개선 | |
| Calzada et al. | Glutamate-induced excitotoxicity in retina: neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers | |
| CN117279653A (zh) | 用于治疗眼部疾病和病症的化合物 | |
| US20060211662A1 (en) | Combination therapy for topical application in the treatment of age-related macular degeneration and ocular hypertension | |
| Tilleul et al. | Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits | |
| CN113797163B (zh) | 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂 | |
| US20030105167A1 (en) | Treatment of opthalmic diseases | |
| Wagh et al. | The effect of forskolin ophthalmic inserts on intraocular pressure in rabbit eyes | |
| Navarro-Partida et al. | Safety and tolerability of topical ophthalmic triamcinolone acetonide-loaded liposomes formulation and evaluation of its biologic activity in patients with diabetic macular edema. Pharmaceutics 2021; 13: 1–17 | |
| Wang et al. | Safety and efficacy of intracapsular tranilast microspheres in experimental posterior capsule opacification | |
| US20060211660A1 (en) | Combination therapy for topical application in the treatment of dry eye syndrome | |
| Mikheytseva et al. | Ocular hypotensive efficacy of a new liposomal latanoprost formulation administered by different routes for experimental ocular hypertension. | |
| CA2958239A1 (en) | Ophthalmic suspension formulation | |
| CN112294761A (zh) | 一种难溶性药物的眼用胶束制剂 | |
| US20040076682A1 (en) | Novel ophthalmic compositions | |
| WO2026078034A1 (en) | Sitagliptin for use in retinal diseases with neovascularization | |
| WO2022156372A1 (zh) | 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂 | |
| US20230405024A1 (en) | Novel nano-formulation of cannabidiol (cbd) and other cannabinoids for treatment of ocular disorders | |
| WO2006053150A2 (en) | Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension |